A scalable solution for isolating human multipotent
clinical-grade neural stem cells from ES precursors

J 2019

A scalable solution for isolating human multipotent clinical-grade neural stem cells from ES precursors

BOHAČIAKOVÁ, Dáša, Marian HRUSKA-PLOCHAN, Rachel TSUNEMOTO, Wesley D. GIFFORD, Shawn P. DRISCOLL et. al.

Základní údaje

Originální název

A scalable solution for isolating human multipotent clinical-grade neural stem cells from ES precursors

Autoři

BOHAČIAKOVÁ, Dáša (703 Slovensko, domácí), Marian HRUSKA-PLOCHAN (840 Spojené státy), Rachel TSUNEMOTO (840 Spojené státy), Wesley D. GIFFORD (840 Spojené státy), Shawn P. DRISCOLL (840 Spojené státy), Thomas D. GLENN (840 Spojené státy), Stephanie WU (840 Spojené státy), Silvia MARSALA (840 Spojené státy), Michael NAVARRO (840 Spojené státy), Takahiro TADOKORO (840 Spojené státy), Stefan JUHAS (203 Česká republika), Jana JUHASOVA (203 Česká republika), Oleksandr PLATOSHYN (840 Spojené státy), David PIPER (840 Spojené státy), Vickie SHECKLER (840 Spojené státy), Dara DITSWORTH (840 Spojené státy), Samuel L. PFAFF (840 Spojené státy) a Martin MARSALA (840 Spojené státy, garant)

Vydání

Stem Cell Research & Therapy, London, BMC, 2019, 1757-6512

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10601 Cell biology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.116

Kód RIV

RIV/00216224:14110/19:00107589

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1186/s13287-019-1163-7

UT WoS

000461323900008

Klíčová slova anglicky

Human embryonic stem cell (hESC); Neural stem cell (NSC); Spinal cord; Amyotrophic lateral sclerosis (ALS); Spinal traumatic injury; Bioinformatic tools to study xenografts

Štítky

14110517, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 14. 4. 2020 14:18, Mgr. Tereza Miškechová

Anotace

V originále

Background: A well-characterized method has not yet been established to reproducibly, efficiently, and safely isolate large numbers of clinical-grade multipotent human neural stem cells (hNSCs) from embryonic stem cells (hESCs). Consequently, the transplantation of neurogenic/gliogenic precursors into the CNS for the purpose of cell replacement or neuroprotection in humans with injury or disease has not achieved widespread testing and implementation. Methods: Here, we establish an approach for the in vitro isolation of a highly expandable population of hNSCs using the manual selection of neural precursors based on their colony morphology (CoMo-NSC). The purity and NSC properties of established and extensively expanded CoMo-NSC were validated by expression of NSC markers (flow cytometry, mRNA sequencing), lack of pluripotent markers and by their tumorigenic/differentiation profile after in vivo spinal grafting in three different animal models, including (i) immunodeficient rats, (ii) immunosuppressed ALS rats (SOD1G93A), or (iii) spinally injured immunosuppressed minipigs. Results: In vitro analysis of established CoMo-NSCs showed a consistent expression of NSC markers (Sox1, Sox2, Nestin, CD24) with lack of pluripotent markers (Nanog) and stable karyotype for more than 15 passages. Gene profiling and histology revealed that spinally grafted CoMo-NSCs differentiate into neurons, astrocytes, and oligodendrocytes over a 2–6-month period in vivo without forming neoplastic derivatives or abnormal structures. Moreover, transplanted CoMo-NSCs formed neurons with synaptic contacts and glia in a variety of host environments including immunodeficient rats, immunosuppressed ALS rats (SOD1G93A), or spinally injured minipigs, indicating these cells have favorable safety and differentiation characteristics. Conclusions: These data demonstrate that manually selected CoMo-NSCs represent a safe and expandable NSC population which can effectively be used in prospective human clinical cell replacement trials for the treatment of a variety of neurodegenerative disorders, including ALS, stroke, spinal traumatic, or spinal ischemic injury.

Návaznosti

GJ15-18316Y, projekt VaV

Název: Úloha microRNA v řízení buněčného dělení a diferenciace lidských embryonálních kmenových buněk do neurálních kmenových buněk. (Akronym: miRNA v diferenciaci lidských EK buněk)

Investor: Grantová agentura ČR, Úloha microRNA v řízení buněčného dělení a diferenciace lidských embryonálních kmenových buněk do neurálních kmenových buněk

GJ18-25429Y, projekt VaV

Název: Funkční studie mikroRNA u nerálních kmenových buněk v průběhu diferenciace

Investor: Grantová agentura ČR, Funkční studie mikroRNA u nerálních kmenových buněk v průběhu diferenciace

Citovat

BOHAČIAKOVÁ, Dáša, Marian HRUSKA-PLOCHAN, Rachel TSUNEMOTO, Wesley D. GIFFORD, Shawn P. DRISCOLL, Thomas D. GLENN, Stephanie WU, Silvia MARSALA, Michael NAVARRO, Takahiro TADOKORO, Stefan JUHAS, Jana JUHASOVA, Oleksandr PLATOSHYN, David PIPER, Vickie SHECKLER, Dara DITSWORTH, Samuel L. PFAFF a Martin MARSALA. A scalable solution for isolating human multipotent clinical-grade neural stem cells from ES precursors. Stem Cell Research & Therapy. London: BMC, 2019, roč. 10, č. 83, s. 1-19. ISSN 1757-6512. Dostupné z: https://dx.doi.org/10.1186/s13287-019-1163-7.

@article{1550212,
   author = {Bohačiaková, Dáša and HruskaandPlochan, Marian and Tsunemoto, Rachel and Gifford, Wesley D. and Driscoll, Shawn P. and Glenn, Thomas D. and Wu, Stephanie and Marsala, Silvia and Navarro, Michael and Tadokoro, Takahiro and Juhas, Stefan and Juhasova, Jana and Platoshyn, Oleksandr and Piper, David and Sheckler, Vickie and Ditsworth, Dara and Pfaff, Samuel L. and Marsala, Martin},
   article_location = {London},
   article_number = {83},
   doi = {http://dx.doi.org/10.1186/s13287-019-1163-7},
   keywords = {Human embryonic stem cell (hESC); Neural stem cell (NSC); Spinal cord; Amyotrophic lateral sclerosis (ALS); Spinal traumatic injury; Bioinformatic tools to study xenografts},
   language = {eng},
   issn = {1757-6512},
   journal = {Stem Cell Research & Therapy},
   title = {A scalable solution for isolating human multipotent clinical-grade neural stem cells from ES precursors},
   url = {https://stemcellres.biomedcentral.com/track/pdf/10.1186/s13287-019-1163-7},
   volume = {10},
   year = {2019}
}

TY  - JOUR
ID  - 1550212
AU  - Bohačiaková, Dáša - Hruska-Plochan, Marian - Tsunemoto, Rachel - Gifford, Wesley D. - Driscoll, Shawn P. - Glenn, Thomas D. - Wu, Stephanie - Marsala, Silvia - Navarro, Michael - Tadokoro, Takahiro - Juhas, Stefan - Juhasova, Jana - Platoshyn, Oleksandr - Piper, David - Sheckler, Vickie - Ditsworth, Dara - Pfaff, Samuel L. - Marsala, Martin
PY  - 2019
TI  - A scalable solution for isolating human multipotent clinical-grade neural stem cells from ES precursors
JF  - Stem Cell Research & Therapy
VL  - 10
IS  - 83
SP  - 1-19
EP  - 1-19
PB  - BMC
SN  - 17576512
KW  - Human embryonic stem cell (hESC)
KW  - Neural stem cell (NSC)
KW  - Spinal cord
KW  - Amyotrophic lateral sclerosis (ALS)
KW  - Spinal traumatic injury
KW  - Bioinformatic tools to study xenografts
UR  - https://stemcellres.biomedcentral.com/track/pdf/10.1186/s13287-019-1163-7
L2  - https://stemcellres.biomedcentral.com/track/pdf/10.1186/s13287-019-1163-7
N2  - Background: A well-characterized method has not yet been established to reproducibly, efficiently, and safely isolate large numbers of clinical-grade multipotent human neural stem cells (hNSCs) from embryonic stem cells (hESCs). Consequently, the transplantation of neurogenic/gliogenic precursors into the CNS for the purpose of cell replacement or neuroprotection in humans with injury or disease has not achieved widespread testing and implementation. Methods: Here, we establish an approach for the in vitro isolation of a highly expandable population of hNSCs using the manual selection of neural precursors based on their colony morphology (CoMo-NSC). The purity and NSC properties of established and extensively expanded CoMo-NSC were validated by expression of NSC markers (flow cytometry, mRNA sequencing), lack of pluripotent markers and by their tumorigenic/differentiation profile after in vivo spinal grafting in three different animal models, including (i) immunodeficient rats, (ii) immunosuppressed ALS rats (SOD1G93A), or (iii) spinally injured immunosuppressed minipigs. Results: In vitro analysis of established CoMo-NSCs showed a consistent expression of NSC markers (Sox1, Sox2, Nestin, CD24) with lack of pluripotent markers (Nanog) and stable karyotype for more than 15 passages. Gene profiling and histology revealed that spinally grafted CoMo-NSCs differentiate into neurons, astrocytes, and oligodendrocytes over a 2–6-month period in vivo without forming neoplastic derivatives or abnormal structures. Moreover, transplanted CoMo-NSCs formed neurons with synaptic contacts and glia in a variety of host environments including immunodeficient rats, immunosuppressed ALS rats (SOD1G93A), or spinally injured minipigs, indicating these cells have favorable safety and differentiation characteristics. Conclusions: These data demonstrate that manually selected CoMo-NSCs represent a safe and expandable NSC population which can effectively be used in prospective human clinical cell replacement trials for the treatment of a variety of neurodegenerative disorders, including ALS, stroke, spinal traumatic, or spinal ischemic injury.
ER  -

BOHAČIAKOVÁ, Dáša, Marian HRUSKA-PLOCHAN, Rachel TSUNEMOTO, Wesley D. GIFFORD, Shawn P. DRISCOLL, Thomas D. GLENN, Stephanie WU, Silvia MARSALA, Michael NAVARRO, Takahiro TADOKORO, Stefan JUHAS, Jana JUHASOVA, Oleksandr PLATOSHYN, David PIPER, Vickie SHECKLER, Dara DITSWORTH, Samuel L. PFAFF a Martin MARSALA. A scalable solution for isolating human multipotent clinical-grade neural stem cells from ES precursors. \textit{Stem Cell Research \&{} Therapy}. London: BMC, 2019, roč.~10, č.~83, s.~1-19. ISSN~1757-6512. Dostupné z: https://dx.doi.org/10.1186/s13287-019-1163-7.

Podrobný výpis o publikaci